Platforma “BioPhoT” aicina uz analītisku klātienes semināru par otrā uzsaukuma industrijas ekspertu paneļa rezultātiem, projektu snieguma izvērtējumu un galvenajām atziņām par pētniecības ideju ceļu uz tirgu.
The workshop is expected to provide an in-depth look back at the BioPhoT Call 2 Industry Panel, where teams of scientists received direct, market-oriented feedback from international experts.
The aim of the event is to analyse the performance of applications, identify common strengths and weaknesses, and provide practical advice for researchers working on the further development and commercialisation of their ideas.
The workshop is especially aimed at BioPhoT Call 2 applicants, project mentors and researchers planning to participate in future calls, as well as anyone interested in the commercialisation of science and collaboration with industry.
Reģistrācija pasākumam atvērta līdz 23. februārim: https://luma.com/9nio1zds
Seminar programme
13.45-14.00 Arrival and registration of participants
14.00-14.10 Introductory remarks (Osvalds Pugovičs, CEO of BioPhoT)
14.10-15.00 Analysis of results - strengths and weaknesses of reports, lessons learned, recommendations for the next call (Andris Baumanis, BioPhoT mentor, Tamar Raz and Daniel Carew, experts in Indian studies)
15.00-15.30 Q&A session, discussion
About the Industry Panel Experts
Dr Tamar Raz is a life sciences and medical innovation expert with more than 20 years of experience in technology transfer, business development and commercialisation of medical innovations. She has previously led Hadasit - Hadassah Medical Organisation Technology Transfer Company, worked at Tel Aviv University Technology Transfer Company Ramot and founded a biomedical start-up. Dr Raz's day-to-day work includes early-stage biomedical project development, academia-industry partnerships and investor attraction.
Dr Daniel Carew is a venture capital investor in science-intensive ideas and a partner in a fund Join Capital, focusing on early-stage strategic and defence technologies in Europe. His experience includes investments in space, quantum technologies, materials science, climate technologies, robotics and biotechnology, as well as work with university companies and deep technology commercialisation.